Cargando…
Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196867/ https://www.ncbi.nlm.nih.gov/pubmed/35712102 http://dx.doi.org/10.3389/fmed.2022.915828 |
_version_ | 1784727276540133376 |
---|---|
author | Fetter, Tanja Braegelmann, Christine de Vos, Luka Wenzel, Joerg |
author_facet | Fetter, Tanja Braegelmann, Christine de Vos, Luka Wenzel, Joerg |
author_sort | Fetter, Tanja |
collection | PubMed |
description | Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The typical histopathologic pattern of skin lesions is named interface dermatitis and characterized by a lymphocytic infiltrate and necroptotic keratinocytes at the dermo-epidermal junction. Other histopathologic patterns primarily involve the dermis or subcutis, depending on the subtype. One critical mechanism in CLE is the chronic reactivation of innate and adaptive immune pathways. An important step in this process is the recognition of endogenous nucleic acids released from dying cells by various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic receptors. Crucial cells in CLE pathogenesis comprise plasmacytoid dendritic cells (pDCs) as major producers of type I IFN, T cells exerting cytotoxic effects, and B cells, previously believed to contribute via secretion of autoantibodies. However, B cells are increasingly considered to have additional functions, supported by studies finding them to occur in highest numbers in chronic discoid lupus erythematosus (CDLE), a subtype in which autoantibodies are often absent. More precise knowledge of how CLE subtypes differ pathophysiologically may allow a tailored pharmacotherapy in the future, taking into account the specific molecular signature in relation to the morphologic subtype. |
format | Online Article Text |
id | pubmed-9196867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91968672022-06-15 Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus Fetter, Tanja Braegelmann, Christine de Vos, Luka Wenzel, Joerg Front Med (Lausanne) Medicine Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The typical histopathologic pattern of skin lesions is named interface dermatitis and characterized by a lymphocytic infiltrate and necroptotic keratinocytes at the dermo-epidermal junction. Other histopathologic patterns primarily involve the dermis or subcutis, depending on the subtype. One critical mechanism in CLE is the chronic reactivation of innate and adaptive immune pathways. An important step in this process is the recognition of endogenous nucleic acids released from dying cells by various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic receptors. Crucial cells in CLE pathogenesis comprise plasmacytoid dendritic cells (pDCs) as major producers of type I IFN, T cells exerting cytotoxic effects, and B cells, previously believed to contribute via secretion of autoantibodies. However, B cells are increasingly considered to have additional functions, supported by studies finding them to occur in highest numbers in chronic discoid lupus erythematosus (CDLE), a subtype in which autoantibodies are often absent. More precise knowledge of how CLE subtypes differ pathophysiologically may allow a tailored pharmacotherapy in the future, taking into account the specific molecular signature in relation to the morphologic subtype. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9196867/ /pubmed/35712102 http://dx.doi.org/10.3389/fmed.2022.915828 Text en Copyright © 2022 Fetter, Braegelmann, de Vos and Wenzel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Fetter, Tanja Braegelmann, Christine de Vos, Luka Wenzel, Joerg Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title | Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title_full | Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title_fullStr | Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title_full_unstemmed | Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title_short | Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus |
title_sort | current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196867/ https://www.ncbi.nlm.nih.gov/pubmed/35712102 http://dx.doi.org/10.3389/fmed.2022.915828 |
work_keys_str_mv | AT fettertanja currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus AT braegelmannchristine currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus AT devosluka currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus AT wenzeljoerg currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus |